Ge Long Hui·2025-09-29 05:33Core Insights - Bank of America Securities reports that WuXi AppTec has maintained a 33% market share in the oncology drug development sector since 2021, indicating strong performance in active client engagement [1] - The revenue from non-oncology in vivo pharmacology business has grown by 42% in the first half of this year, showcasing robust demand [1] - Despite intensified price competition in the industry, the value of new preclinical orders has increased by 14.5% year-on-year, reflecting ongoing growth in the sector [1] Financial Projections - WuXi AppTec's management anticipates revenue growth exceeding 20% for the current year, supported by a client base of approximately 2,550 [1] - Based on favorable prospects in biological and chemical businesses, revenue forecasts for 2026 and 2027 have been raised by 0.2% and 0.3% respectively [1] - The forecast for gross margin has been adjusted upwards due to enhanced project values and improved production efficiency, leading to an increase in earnings per share estimates by 0.4% and 0.8% [1] Target Price Adjustment - The target price for WuXi AppTec has been raised from HKD 123 to HKD 130.7, with a reiterated "Buy" rating reflecting confidence in the company's growth trajectory [1]